Shares of Trillium Therapeutics jumped above $17 on Aug. 23 on word Pfizer would buy the Canadian drug developer in a $2.3 billion deal.
Trillium Therapeutics is a biotechnology business based in the US. Trillium Therapeutics shares (TRIL) are listed on the NASDAQ and all prices are listed in US Dollars. Trillium Therapeutics employs 33 staff and has a trailing 12-month revenue of around $43,000.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $17.71 |
| 200-day moving average | $11.96 |
| Wall St. target price | $23.41 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.54 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $N/A from 2021-12-08
| 1 week (2023-09-11) | N/A |
|---|---|
| 1 month (2023-08-18) | N/A |
| 3 months (2023-06-18) | N/A |
| 6 months (2023-03-18) | N/A |
| 1 year (2022-09-18) | N/A |
|---|---|
| 2 years (2021-09-22) | -100.00% |
| 3 years (2020-09-22) | -100.00% |
| 5 years (2018-09-21) | -100.00% |
| Revenue TTM | $43,000 |
|---|---|
| Gross profit TTM | $148,000 |
| Return on assets TTM | -12.74% |
| Return on equity TTM | -21.67% |
| Profit margin | 0% |
| Book value | $2.17 |
| Market Capitalization | $1.9 billion |
TTM: trailing 12 months
We're not expecting Trillium Therapeutics to pay a dividend over the next 12 months.
Trillium Therapeutics's shares were split on a 1:30 basis on 19 November 2014. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trillium Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Trillium Therapeutics shares which in turn could have impacted Trillium Therapeutics's share price.
Over the last 12 months, Trillium Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trillium Therapeutics's is 1.9046. This would suggest that Trillium Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc. , a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.